Biogen Snaps Up Apellis Pharma For $5.6 Billion, But Biogen Dives As Apellis Soars

The $5.6 billion M&A represents a significant financial burden, amounting to 22.4% of BIIB's market capitalization (~$25 billion), raising concerns about short-term cash flow and worsening debt ratios. However, securing Apellis' Syfovre (a treatment for retinal diseases) and its pipeline (including complement C3 inhibitors) provides a non-neurological growth driver. There is also an expected diversification effect on R&D risk due to the failure of the Alzheimer's treatment (TAU).

Following the M&A announcement, the stock price has sharply declined and is currently testing the support level of $300. While the likelihood of breaking through the resistance level of $340 during a short-term rebound appears low, there is potential for an increase to $360 if Apellis reports positive earnings. It is recommended to enter a buy position below $305.

1) Apellis' Syfovre is in the early stages of commercialization following FDA approval, with expectations for accelerated non-neurological growth for BIIB. 2) The sharp rise in Apellis' stock price (+150%+) reflects the market's high expectations. 3) The downward pressure on BIIB's stock price due to the failure of its Alzheimer's treatment has been temporarily alleviated by the announcement of M&A. 4) Future clinical results from Apellis (such as the complement C3 inhibitor) and performance announcements for Syfovre may lead to stock price volatility.